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Red Cell Disorders
Two new glucose-6-phosphate dehydrogenase
mutations causing chronic hemolysis 
We describe two new missense mutations in the
glucose-6-phosphate dehydrogenase (G6PD) gene
associated with chronic hemolytic anemia: muta-
tion 1205CÆA in exon 10 predicts the amino acid
change 402ThrÆAsn in the b-sheet M of the
polypeptide chain, within the dimer interface
(G6PD Covão do Lobo); mutation 1366GÆA in
exon 12 predicts the amino acid substitution
456AspÆHis in the a-helix N, at the protein sur-
face (G6PD Figueira da Foz). 
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The majority of individuals with glucose-6-phosphate
dehydrogenase (G6PD) deficiency are usually asympto-
matic, with normal hematologic parameters, but may
develop acute hemolysis in response to oxidative stress
induced by several drugs, infection or fava bean ingestion
(classes II to IV G6PD variants).1 A small number of
G6PD-deficient patients have rare class I molecular vari-
ants responsible for chronic non-spherocytic hemolytic
anemia of heterogeneous severity; this, too, can be fur-
ther exacerbated by oxidative stress.2 To date more than
60 G6PD class I mutations have been identified, the great
majority being missense mutations present in and around
exon 10, with the corresponding amino acids located
within or close to the subunit interface of the G6PD
dimer.3,4 Structure-function studies have verified that
class I mutations mainly occur at conserved amino acids.5
In this report we present the molecular characteriza-
tion of three severe G6PD-deficient Portuguese patients
with chronic hemolysis from two unrelated families. 
Case #1. A 25-year old Portuguese male presented at
the emergency room complaining of weakness, jaundice
and dark urine for the last 3 days. His spleen was palpa-
ble 15 cm below the left costal margin. He had had
neonatal jaundice, requiring phototherapy, had chronical-
ly yellowish sclera and had had one severe hemolytic
episode in infancy. His hemoglobin concentration was
70 g/L, his mean cell volume 101 fL, reticulocytes 12%,
unconjugated serum bilirubin 58.1 *mol/L (normal range:
3-20); a peripheral blood smear showed some erythro-
cytes with oxidative stress. Out of the hemolytic episode,
he has a just palpable spleen and moderate macrocytic
anemia (Table 1).
Case #2. At the age of 3 years old, a Portuguese boy
presented with a febrile episode and jaundice. His spleen
was not palpable. His hemoglobin concentration was 86
g/L and unconjugated serum bilirubin: 51 mmol/L. He had
a history of neonatal jaundice, requiring phototherapy,
but no other important hemolytic episodes. A family
study revealed a maternal uncle (Case 3) with chronic
jaundice and a palpable spleen who had had several
episodes of hemolytic anemia (data on Table 1). To
exclude other causes of chronic non-spherocytic hemo-
lytic anemia, the samples were screened for abnormal
hemoglobins and common glycolytic enzyme deficien-
cies.
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Table 1. Hematologic parameters, G6PD activity out of the hemolytic crisis and molecular data.
Patient Age Hb MCV Retics Unc Bilir LDH Serum G6PD (TA)n G6PD Amino acid
(Yr) (g/L) (fL) (% of RBC) (mmol/L) (U/L) Ferritin (ng/mL) (% of N) in UGT1 Mutation substitution
Patient #1 26 112 108 7 35.3 416 1290 0.9 TA6/ TA6 1205CÆA 402ThrÆAsn
Mother 120 92 0.9 ND ND ND 76 ND 1205CÆA/NF
Patient #2 10 131 101 5.2 57.3 512 120 2.9 TA7/TA7 1366GÆA 456AspÆHis
Mother 131 97 ND ND ND ND 97 ND 1366GÆA/NF
Patient #3 (Maternal uncle) 41 137 110 4.9 39.1 ND ND 1.2 TA7/TA6 1366GÆA
456AspÆHis
Hb: hemoglobin (normal values: adult females 120-150 g/L; adult males 135-170 g/L; 6-12 years 115-150 g/L); MCV: mean cell volume (normal values adults 92±9 fL;
6-12 years 75-95 fL); Retics: Reticulocytes (normal values: 0-2%); Unc Bilir: unconjugated bilirubin (normal values: 3-20 mmol/L); LDH: lactate dehydrogenase
(normal values: 100-190 U/L); Serum Ferritin (normal values: age 4 months to 16 years 20-200 ng/mL; adult males 30-400 ng/mL); ND: not determined; NF: not
found. Screening for hemoglobinopathies detected a heterozygosity for the Hb variant City of Hope (CD.69 GGTÆAGT) in patient 1; this variant has not been associat-
ed with any phenotypic changes. None of the patients has detectable hemosiderinuria between the hemolytic episodes.
Figure 1. Human G6PD dimer showing mutated residues Thr402
(shown as red spheres) within the dimer interface, and Asp456
(shown as pink spheres) located within alpha helix N. The structur-
al NADP+ molecules are shown as stick models and the catalytic
Lys205 is highlighted in yellow. G6PD subunits are colored in
green and blue. The figure was prepared with PyMOL10 using the
co-ordinates of the human G6PD Canton mutant 1QKI4 (Protein
Data Bank (http://www.rcsb.org/pdb/).
After patients and relatives had given informed con-
sent, genomic DNA was extracted from EDTA peripher-
al blood using standard methods, and G6PD gene exons
2 to 13 were amplified by polymerase chain reaction
(PCR) as described elsewhere.6 PCR products were
screened by single strand conformation polymorphism
(SSCP) analysis and sequenced with the automatic genet-
ic analyzer ABI Prism 310. 
The G6PD gene from patient 1 showed a SSCP mobil-
ity shift in the fragment spanning exon 10 and sequenc-
ing revealed a previously undescribed mutation
1205CÆA, predicting the amino acid change 402
ThrÆAsn. T402 is a poorly conserved residue, located at
the b-sheet M of the polypeptide chain; crystal structure
analysis of human G6PD protein4 showed that T402 is
located at the dimer interface (Figure 1). The T402 side
chains of the two monomers do not make any intersub-
unit contacts and are 5.4Å apart, across the dimer inter-
face. Instead, they are within a distance compatible with
a van der Waals effect of the L420 side chain in b strand
N within the same monomer. Furthermore, b strand N
harbors D421, a residue interacting with the nicoti-
namide ring of the structural NADP+. The T402N muta-
tion would introduce steric hindrance forcing the two
dimers apart. In summary, as suggested for amino acid
substitutions mapping close to this region,7-9 T402N will
both affect the dimer interface and interfere with the
structural NADP+ binding site,4 severely affecting protein
stability. DNA sequencing of the G6PD gene from
patients 2 and 3 revealed a previously undescribed muta-
tion in exon 12, a 1366GÆA substitution, predicting the
amino acid change 456AspÆHis. D456 is located in the
beginning of the a-helix N, further down the polypeptide
carboxylic terminus. Structural analysis showed D456 at
the protein surface, far away from the dimer interface
(Figure 1). D456 forms a strong salt bridge with R454
within helix N which is further stabilized by interactions
with D282 and D286 in helix J. Replacing D456 by His
would partially disrupt this network of salt bridges.
Furthermore, the positively charged His side chain at this
position will certainly introduce unfavorable electrostatic
interactions with R459, R454 and K293, affecting protein
structure and stability. Although not located in the imme-
diate vicinity of the active site, D456 is highly conserved
from bacteria to humans reflecting important functional
and/or structural features; hence D456H is in accordance
with the general concept that the clinically more severe
G6PD deficiencies are mainly associated with mutations
at conserved amino acids.5
Both mutations were confirmed by restriction enzyme
digestion and no other mutations were detected in the
remaining exons or adjacent regions of the G6PD gene.
The screening of 100 alleles from a control group failed
to detect these mutations. The new variants T402N and
D456H were named G6PD Covão do Lobo and G6PD
Figueira da Foz, respectively, after the patients’ place of
birth.
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Red Cell Disorders
Prevalence and severity of liver disease in
patients with b thalassemia major.
A single-institution fifteen-year experience
During the last years, liver disease has emerged
as a major cause of mortality in patients with b tha-
lassemia major (TM).1,2 In spite of its clinical rele-
vance, TM-associated liver damage has been insuf-
ficiently characterized.1,2-5 We therefore retrospec-
tively analyzed all TM patients of our Department
who underwent liver biopsy since 1990.haematologica 2005; 90:1136-1138
(http://www.haematologica.org/journal/2005/8/1136.html)
All patients were being regularly transfused in order to
maintain the pretransfusion hemoglobin level at approxi-
mately 9.5 g/dL. Chelation therapy with desferrioxamine
40–60 mg/kg/day for 5–6 days/week was initiated as soon
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